Vaccination with Messenger RNA (mRNA)
- 1 January 2008
- book chapter
- Published by Springer Nature
- No. 183,p. 221-235
- https://doi.org/10.1007/978-3-540-72167-3_11
Abstract
Both DNA and mRNA can be used as vehicles for gene therapy. Because the immune system is naturally activated by foreign nucleic acids thanks to the presence of Toll-like Receptors (TLR) in endosomes (TLR3, 7, and 8 detect exogenous RNA, while TLR9 can detect exogenous DNA), the delivery of foreign nucleic acids usually induces an immune response directed against the encoded protein. Many preclinical and clinical studies were performed using DNA-based experimental vaccines. However, no such products are yet approved for the human population. Meanwhile, the naturally transient and cytosolically active mRNA molecules are seen as a possibly safer and more potent alternative to DNA for gene vaccination. Optimized mRNA (improved for codon usage, stability, antigen-processing characteristics of the encoded protein, etc.) were demonstrated to be potent gene vaccination vehicles when delivered naked, in liposomes, coated on particles or transfected in dendritic cells in vitro. Human clinical trials indicate that the delivery of mRNA naked or transfected in dendritic cells induces the expected antigen-specific immune response. Follow-up efficacy studies are on the way. Meanwhile, mRNA can be produced in large amounts and GMP quality, allowing the further development of mRNA-based therapies. This chapter describes the structure of mRNA, its possible optimizations for immunization purposes, the different methods of delivery used in preclinical studies, and finally the results of clinical trial where mRNA is the active pharmaceutical ingredient of new innovative vaccines.Keywords
This publication has 30 references indexed in Scilit:
- Intralymphatic Dendritic Cell Vaccination Induces Tumor Antigen–Specific, Skin-Homing T LymphocytesClinical Cancer Research, 2006
- Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cellsJournal of Clinical Investigation, 2005
- Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigenCancer Immunology, Immunotherapy, 2005
- Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccinesCellular and Molecular Life Sciences, 2004
- Cross-presentation of a human tumor antigen delivered to dendritic cells by HSV VP22-mediated protein translocationEuropean Journal of Immunology, 2004
- Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degenerationOphthalmology, 2003
- Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumorsJournal of Clinical Investigation, 2002
- In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodiesEuropean Journal of Immunology, 2000
- Four highly stable eukaryotic mRNAs assemble 3′ untranslated region RNA–protein complexes sharing cis and trans componentsProceedings of the National Academy of Sciences, 1997
- Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo.The Journal of Experimental Medicine, 1996